¿ì²¥³ÉÈËÍø

Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG; Cancers; (2021).

Protection against bovine respiratory syncytial virus in calves vaccinated with adjuvanted modified live vaccine administered in the face of maternal antibody; Vaccine; (2020).

Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report; Pediatric Blood and Cancer; (2020).

Phase I/II study of CPX-351 followed by fludarabine, cytarabine, and granulocyte-colony stimulating factor for children with relapsed acute myeloid leukemia: A report from the children's oncology group; Journal of Clinical Oncology; (2020).

Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration; European Journal of Cancer; (2020).

Morphologic remission status is limited compared to DN flow cytometry: a Children's Oncology Group AAML0531 report; Blood Advances; (2020).

Modeling Transient Abnormal Myelopoiesis Using Induced Pluripotent Stem Cells and CRISPR/Cas9 Technology; Molecular Therapy - Methods and Clinical Development; (2020).

Initial in vivo testing of TPO-receptor agonist eltrombopag in osteosarcoma patient-derived xenograft models by the pediatric preclinical testing consortium; Pediatric Hematology and Oncology; (2020).

Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium; Pediatric Blood and Cancer; (2020).

Error-corrected sequencing strategies enable comprehensive detection of leukemic mutations relevant for diagnosis and minimal residual disease monitoring; BMC Medical Genomics; (2020).

Effect of dexrazoxane on left ventricular systolic function and treatment outcomes in patients with acute myeloid leukemia: A report from the Children's oncology group; Journal of Clinical Oncology; (2020).

Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium; Pediatric Blood and Cancer; (2020).

Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group; Haematologica; (2020).

Aggressive hematopoietic malignancy characterized by biallelic loss of SMARCB1; JCO Precision Oncology; (2020).

A Phase 2 Trial of KIR-Mismatched Unrelated Donor Transplantation Using in Vivo T Cell Depletion with Antithymocyte Globulin in Acute Myelogenous Leukemia: Children's Oncology Group AAML05P1 Study; Biology of Blood and Marrow Transplantation; (2020).

Stability and change in family psychosocial risk over 6 months in pediatric cancer and its association with medical and psychosocial healthcare utilization; Pediatric Blood and Cancer; (2020).

Strong concordance between RNA structural and single nucleotide variants identified via next generation sequencing techniques in primary pediatric leukemia and patient-derived xenograft samples; Genomics and Informatics; (2020).

p27/Kip1 functions as a tumor suppressor and oncoprotein in osteosarcoma; Scientific Reports; (2019).

Screening for Family Psychosocial Risk in Pediatric Hematopoietic Stem Cell Transplantation with the Psychosocial Assessment Tool; Biology of Blood and Marrow Transplantation; (2019).

Risk factors for chemotherapy-induced nausea in pediatric patients receiving highly emetogenic chemotherapy; Pediatric Blood and Cancer; (2019).

Quality of life in pediatric acute myeloid leukemia: Report from the Children's Oncology Group; Cancer Medicine; (2019).

Mentors' perspectives on the successes and challenges of mentoring in the COG Young Investigator mentorship program: A report from the Children's Oncology Group; Pediatric Blood and Cancer; (2019).

A psychosocial clinical care pathway for pediatric hematopoietic stem cell transplantation; Pediatric Blood and Cancer; (2019).

Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group; Pediatric Blood and Cancer; (2019).

Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design; Cell Reports; (2019).

Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia; Leukemia; (2019).

Development of acute lymphoblastic leukemia following treatment for acute myeloid leukemia in children with Down syndrome: A case report and retrospective review of Children's Oncology Group acute myeloid leukemia trials; Pediatric Blood and Cancer; (2019).

Development of a Novel Next-Generation Sequencing Assay for Carrier Screening in Old Order Amish and Mennonite Populations of Pennsylvania; Journal of Molecular Diagnostics; (2019).

Bone marrow transplant and pediatric multiple myeloma; Pediatric Blood and Cancer; (2019).

A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group; Pediatric Blood and Cancer; (2019).

Publisher Correction: The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions (Nature Medicine, (2017), 24, 1, (103-112), 10.1038/nm.4439); Nature Medicine; (2019).

Delivery of care consistent with the psychosocial standards in pediatric cancer: Current practices in the United States; Pediatric Blood and Cancer; (2018).

Acupressure bands do not improve chemotherapy-induced nausea control in pediatric patients receiving highly emetogenic chemotherapy: A single-blinded, randomized controlled trial; Cancer; (2018).

The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions; Nature Medicine; (2018).

Development of chemotherapy with cell-cycle inhibitors for adult and pediatric cancer therapy; Cancer Research; (2018).

CRISPR/Cas9-Directed Reassignment of the GATA1 Initiation Codon in K562 Cells to Recapitulate AML in Down Syndrome; Molecular Therapy - Nucleic Acids; (2017).

Down syndrome and AML: Where do we go from here?; Blood; (2017).

Disease characteristics and prognostic implications of cell-surface FLT3 receptor (CD135) expression in pediatric acute myeloid leukemia: A report from the Children's Oncology Group; Clinical Cancer Research; (2017).

Cytotoxicity of zardaverine in embryonal rhabdomyosarcoma from a Costello syndrome patient; Frontiers in Oncology; (2017).

Recent advances of cell-cycle inhibitor therapies for pediatric cancer; Cancer Research; (2017).

The microtubule network and cell death are regulated by an miR-34a/stathmin 1/ßIIITubulin axis; Molecular Cancer Research; (2017).

Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia; Leukemia Research; (2017).

Opportunities for expanding clinical trial enrollment for relapsed and refractory pediatric acute myeloid leukemia in the United States and Canada; Pediatric Blood and Cancer; (2017).

MicroRNA expression-based model indicates event-free survival in pediatric acute myeloid leukemia; Journal of Clinical Oncology; (2017).

Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program; Pediatric Blood and Cancer; (2017).

Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2017).

Implementing the psychosocial standards in pediatric cancer: Current staffing and services available; Pediatric Blood and Cancer; (2017).

Evaluation of alternative in vivo drug screening methodology: A single mouse analysis; Cancer Research; (2016).

CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML; Blood; (2016).

Initial Testing (Stage 1) of MK-8242—A Novel MDM2 Inhibitor—by the Pediatric Preclinical Testing Program; Pediatric Blood and Cancer; (2016).

Generation of pediatric leukemia xenograft models in NSG-B2m mice: Comparison with NOD/SCID mice; Frontiers in Oncology; (2016).

Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program; Pediatric Blood and Cancer; (2016).

Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program; Pediatric Blood and Cancer; (2016).

Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma; Pediatric Blood and Cancer; (2016).

Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma; Oncotarget; (2016).

Domestic pigs are susceptible to infection with influenza B viruses; Journal of Virology; (2015).

A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: A Children's Oncology Group Phase I Consortium report; Pediatric Blood and Cancer; (2015).

Vorinostat enhances cytotoxicity of SN-38 and temozolomide in ewing sarcoma cells and activates STAT3/AKT/MAPK pathways; PLoS ONE; (2015).

Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric Cancer Models in the Pediatric Preclinical Testing Program; Clinical Cancer Research; (2015).

Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane^®) by the Pediatric Preclinical Testing Program (PPTP); Pediatric Blood and Cancer; (2015).

Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2015).

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673; Pediatric Blood and Cancer; (2015).

Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2015).

Disruption of Annexin II /p11 interaction suppresses leukemia cell binding, homing and engraftment, and sensitizes the leukemia cells to chemotherapy; PLoS ONE; (2015).

Collaborative efforts driving progress in pediatric acute myeloid leukemia; Journal of Clinical Oncology; (2015).

Challenges in converting Acute Myeloid Leukemia (AML) genomics into AML clinical trials; Journal of Clinical Oncology; (2015).

Acute myeloid leukemia in children and adolescents: Identification of new molecular targets brings promise of new therapies; Hematology (United States); (2015).

Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2014).

Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma; PLoS ONE; (2014).

Initial testing (stage 1) of the polo-like kinase inhibitor volasertib (BI 6727), by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2014).

Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2014).

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program; Pediatric Blood and Cancer; (2014).

Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2014).

Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2014).

Initial solid tumor testing (Stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2014).

Oncolytic viruses for potential osteosarcoma therapy; Advances in Experimental Medicine and Biology; (2014).

BIRC5 expression is a poor prognostic marker in Ewing sarcoma; Pediatric Blood and Cancer; (2013).

A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma; Frontiers in Oncology; (2013).

Xenograft and genetically engineered mouse model systems of osteosarcoma and Ewing's sarcoma: Tumor models for cancer drug discovery; Expert Opinion on Drug Discovery; (2013).

Outcomes of Allogeneic Hematopoietic cell transplantation in patients with Dyskeratosis Congenita; Biology of Blood and Marrow Transplantation; (2013).

Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2013).

Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2013).

Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2013).

Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2013).

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2013).

Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2013).

Testing of the Akt/PKB inhibitor MK-2206 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).

Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).

Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).

Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).

Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).

Progress of oncolytic viruses in sarcomas; Expert Review of Anticancer Therapy; (2012).

Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).

Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling; Pediatric Blood and Cancer; (2012).

Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).

Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).

Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).

Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).

Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).

Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2012).

Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2011).

Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2011).

Initial testing of lenalidomide by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2011).

Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts; Cancer; (2011).

Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2011).

Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer; Cancer Chemotherapy and Pharmacology; (2011).

Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2010).

Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2010).

Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2010).

Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2010).

Initial testing (stage 1) of AZD6244 (ARRY-142886) by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2010).

Stage 2 combination testing of rapamycin with cytotoxic agents by the pediatric preclinical testing program; Molecular Cancer Therapeutics; (2010).

R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts; Pediatric Blood and Cancer; (2010).

Past, present and future of therapies in pediatric sarcomas; Future Oncology; (2010).

Moving towards non-invasive assessments of prognosis in osteosarcoma; Pediatric Blood and Cancer; (2010).

Intracranial hemorrhage in alloimmune thrombocytopenia: Stratified management to prevent recurrence in the subsequent affected fetus; American Journal of Obstetrics and Gynecology; (2010).

Initial testing of topotecan by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2010).

Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2010).

Initial testing of the Aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP); Pediatric Blood and Cancer; (2010).

Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma; Cancer Chemotherapy and Pharmacology; (2009).

Initial testing of Aplidin by the pediatric pre-clinical testing program; Pediatric Blood and Cancer; (2009).

Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2009).

Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2009).

Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2009).

Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo; Clinical Cancer Research; (2009).

Development of IGF-IR inhibitors in pediatric sarcomas; Current Oncology Reports; (2009).

Initial testing of the VEGFR inhibitor AZD2171 by the Pediatric Preclinical Testing Program; Pediatric Blood and Cancer; (2008).

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2008).

Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2008).

The combination of clofarabine and cytarabine in pediatric relapsed acute lymphoblastic leukemia: A case report; Chemotherapy; (2008).

Successful outcome with tandem myeloablative chemotherapy and autologous peripheral blood stem cell transplants in a patient with atypical teratoid/rhabdoid tumor of the central nervous system; Journal of Neuro-Oncology; (2008).

Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2008).

Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2008).

Initial testing of cisplatin by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2008).

Initial testing of dasatinib by the pediatric preclinical testing program; Pediatric Blood and Cancer; (2008).

The pediatric preclinical testing program: Description of models and early testing results; Pediatric Blood and Cancer; (2007).

The neuroradiological findings in a case of Revesz syndrome; Pediatric Radiology; (2007).

The folate receptor α is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate; Clinical Cancer Research; (2007).

Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma; Clinical Cancer Research; (2007).

Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia; Obstetrics and Gynecology; (2006).

Dickkopf 3 Inhibits Invasion and Motility of Saos-2 Osteosarcoma Cells by Modulating the Wnt-β-Catenin Pathway; Cancer Research; (2004).

Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults; Journal of Clinical Oncology; (2003).

Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma; Cancer; (2003).

Imatinib Mesylate in Philadelphia Chromosome-Positive Leukemia of Childhood; Cancer; (2003).

A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia; Leukemia; (2003).

Ecteinascidin-743 inhibits activated but not constitutive transcription; Cancer Research; (2002).

The prevalence of TB infection in a population of homeless persons in Philadelphia; Chest; (1996).